Powered by RND
PoddsändningarVetenskapBioCentury This Week
Lyssna på BioCentury This Week i appen
Lyssna på BioCentury This Week i appen
(2 266)(249 698)
Spara kanal
väckarklocka
Sleeptimer

BioCentury This Week

Podcast BioCentury This Week
BioCentury
BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and invest...

Tillgängliga avsnitt

5 resultat 296
  • Ep. 286 - Sofinnova’s Pan-European Accelerator, China Biotechs, Trump Tariffs
    European venture firm Sofinnova Partners is expanding the reach of its Biovelocita accelerator beyond Italy to stretch across the greater continent. On the latest BioCentury This Week podcast, BioCentury’s editors discuss how Biovelocita became the largest life sciences accelerator in Europe. The editors also discuss Novo Nordisk's latest addition to its obesity pipeline via a deal in China, and how the partnership reflects the state of cross-border dealmaking more broadly. And Washington Editor Steve Usdin assesses President Trump’s threat to impose 25% tariffs on pharmaceutical imports and provides an update on how FDA’s staff is navigating the policies of the new administration. Finally, Editor in Chief Simone Fishburn discusses BioCentury's upcoming Grand Rounds meetings.View full story: https://www.biocentury.com/article/65543800:00 - Introduction02:25 - Sofinnova’s Pan-European Accelerator08:27 - China Biotechs14:59 - Trump TariffsTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text
    --------  
    24:30
  • Ep. 285 - BIO's Trump 2.0 Plan. Plus: Autoimmune CAR Ts & Telix's Radiopharma Play
    BIO is engaging with President Donald Trump to protect and improve FDA. It’s also hoping biopharmas can dodge tariffs and find paths to modify the Inflation Reduction Act and reinstate pediatric priority review vouchers. On the latest BioCentury This Week podcast, Washington Editor Steve Usdin delivers takeaways from his conversation with John Crowley, CEO of the industry trade group.BioCentury’s editors also discuss how autoimmune CAR T companies are competing for resources and the end-to-end radiopharma ambitions of Telix Pharmaceuticals. A 2023 landscape on the radiopharma space can be found here.View full story: https://www.biocentury.com/article/65537000:00 - Introduction02:09 - BIO's Trump 2.0 Plan14:00 - Autoimmune CAR Ts21:05 - Telix's Radiopharma PlayTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text
    --------  
    28:26
  • Ep. 284 - Takeaways from the East-West Summit
    While the culling of companies in the biotech bear market may have yet to subside, creative cross-border deal-making on innovative assets is spreading across Asia’s Arc of Innovation. Sciwind Biosciences Co. Ltd.’s Jing Shu and A*Star’s Lisa Ooi join BioCentury to wrap up the 4th annual BioCentury-BayHelix East-West Biopharma Summit in Singapore by discussing deal-making trends, the rise of new technologies and the deepening of biotech ecosystems from India to Japan.View full story: https://www.biocentury.com/article/65531800:00 - Introduction01:58 - Key Takeaways08:42 - Innovation in Japan and India12:54 - Building Biotech Ecosystems31:14 - NewCo ModelTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text
    --------  
    41:27
  • Ep. 283 - Makary’s FDA Agenda, Amylin in Obesity and Life After DEI
    The almost certain confirmation of Marty Makary as FDA commissioner this month will cap a transition marked by internal upheaval and political infighting. On the latest BioCentury This Week podcast, BioCentury’s editors discuss Thursday’s confirmation hearing for President Donald Trump’s pick to lead the agency and Makary's hints at what we can expect from his agenda.The editors also discuss whether the advantages of amylin agonists could help the therapies outshine GLP-1 in obesity, why the latest weight loss data from CagriSema weighed on shares of Novo Nordisk, and a call to deliver on the meritocracy ideal, now that DEI is dead.View full story: https://www.biocentury.com/article/65530200:00 - Introduction01:10 - Makary’s FDA Agenda10:50 - Amylin in Obesity24:21 - Life After DEITo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text
    --------  
    31:30
  • Ep. 282 - CRISPR Lessons: Plus, AbbVie Enters Obesity
    The track record of biotechs launched to create curative therapies using CRISPR-Cas9 provides new insights into the old debate over whether platform companies should validate their technology on established targets or pursue new ones. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the lessons learned by this small group of companies since their launch a decade ago. They also discuss the entrance of AbbVie into the obesity race via a $350 million deal with Gubra for a clinical stage amylin agonist — does it signal AbbVie’s belief in amylin monotherapy, or will the company be hunting for more obesity assets? The editors also talk about recommendations to streamline the early-stage development of rare disease therapies in the U.S.View full story: https://www.biocentury.com/article/65521400:00 - Introduction00:36 - CRISPR Companies09:22 - AbbVie Enters Obesity Race17:19 - Rare Disease Drug ChallengesTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text
    --------  
    23:46

Fler podcasts i Vetenskap

Om BioCentury This Week

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.
Podcast-webbplats

Lyssna på BioCentury This Week, Fasciaguiden och många andra poddar från världens alla hörn med radio.se-appen

Hämta den kostnadsfria radio.se-appen

  • Bokmärk stationer och podcasts
  • Strömma via Wi-Fi eller Bluetooth
  • Stödjer Carplay & Android Auto
  • Många andra appfunktioner
Sociala nätverk
v7.13.0 | © 2007-2025 radio.de GmbH
Generated: 3/28/2025 - 9:49:03 PM